Results of the phase II LUX-Lung-2 study focusing on patients with EGFR-mutated non-small cell lung cancer have been reported and demonstrated a 61% response rate, PFS of 14 months and median survival of 2 years [120]. Here, EGFR is linked to non-small cell lung carcinoma.